2011-06-01T13:19:20-04:00 2010-09-30 GRANT THORNTON LLP 666 THIRD AVENUE NEW YORK NY 100174011 990 2009-10-01 133163817 THE FOUNDATION FOR AIDS RESEARCH FOUN 2128061600 120 wall street 13TH FLOOR NEW YORK NY 100053908 BRADLEY JENSEN 2011-05-31 true 2125429609 2009 2016-02-24 21:20:13Z AMFAR AIDS RESEARCH FOUNDATION KEVIN FROST 120 WALL STREET 13TH FLOOR new york NY 10005 35979190 false X WWW.AMFAR.ORG X 1983 NY amfar is dedicated to ending the global aids epidemic through innovative research. 19 19 96 135 0 0 20760601 21965059 0 0 -530822 506704 228155 2889638 20457934 25361401 5230871 4604199 0 0 8171364 7735764 492575 483987 4221300 10774953 10930086 24669763 23754036 -4211829 1607365 33507816 35804429 5274457 5238663 28233359 30565766 The Foundation for AIDS Research is an international not-for profit organization incorporated in New York in 1989. amfAR was formed through the unification in 1985 of two not-for-profit organizations, the AIDS Medical Foundation ("AMF"), incorporated in New York in April 1983, and the National AIDS Research Foundation, incorporated in California in August 1985. First based in California, amfAR transferred its legal domicile to New York in 1989, using the initial incorporation documents of AMF, making it AMF's legal successor. amfAR has offices in New York, NY, Washington, D.C., and Bangkok, Thailand. On March 7, 2005, the board of trustees of the American Foundation for AIDS Research approved a change in legal name to "The Foundation for AIDS Research." On October 18, 2005, the New York State Department of State approved this change. In addition, the Foundation has secured approval for Doing Business As (DBA) the following: - American Foundation for AIDS Research - amfAR - AIDS Researc false false 6336858 1716863 0 RESEARCH: amfAR supports research projects that explore novel approaches to scientifically sound but untested hypotheses in all areas of research on HIV/AIDS, funding goal-oriented studies that often lack the preliminary data required for support from traditional grant-makers. The Foundation plays a vital role in HIV/AIDS research, identifying critical gaps in knowledge and providing essential seed money that enables grantees and fellows to test the merits of new concepts or technologies that subsequently can be validated through large-scale studies, such as those funded by the National Institutes of Health. For further details, see Schedule o. 5480583 2110078 0 TREAT ASIA: amfAR's TREAT Asia program (Therapeutics Research, Education, and AIDS Training in Asia) involves a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of HIV/AIDS treatments across Asia and the Pacific. The TREAT Asia Network encompasses 23 adult and 20 pediatric sites throughout the region, which collaborate on a variety of projects. Eight papers based on the network's research were published in U.S. and international scientific journals in 2010. For further details, see Schedule o. 2445829 0 0 EDUCATION AND INFORMATION: amfAR seeks to translate and disseminate information on important AIDS-related research, treatment, prevention, and policy issues for diverse audiences and to stimulate broad awareness of the need for better treatment and prevention methods. amfAR also publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policy makers in communicating the need for continued research to develop new methods of prevention, treatment, and, ultimately, a cure for AIDS. For further details, see Schedule O. 1744743 657257 0 MSM Initiative 1569506 120000 0 public policy 3314249 777257 0 17577519 true true false true false false true false true true true false false true true true false true true false false true false true false false false false false false false false true false false false false false false false false true 77 0 true 96 true false true TH false false false false false false false 19 19 false false false false false false false true true false false true true true true true true true true false AL AK AZ AR CA CO CT FL GA HI IL KS KY LA ME MD MA MI MN MS NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X BRADLEY JENSEN 2128061703 120 WALL STREET 13TH FLOOR new york NY 100053908 Dame Elizabeth Taylor 1.0 X 0 0 0 Mathilde Krim PhD 1.0 X 0 0 0 Kenneth Cole 1.0 X X 0 0 0 Patricia J Matson 1.0 X X 0 0 0 John C Simons 1.0 X 0 0 0 Wallace Sheft CPA 1.0 X X 0 0 0 DIANE L TAYLOR 1.0 X X 0 0 0 Arlen H Andelson 1.0 X 0 0 0 Harry Belafonte 1.0 X 0 0 0 David Bohnett 1.0 X 0 0 0 Zev Braun 1.0 X 0 0 0 Jonathan S Canno 1.0 X 0 0 0 Donald Capoccia 1.0 X 0 0 0 R Martin Chavez PhD 1.0 X 0 0 0 Jane B Eisner 1.0 X 0 0 0 Michael J Klingensmith 1.0 X 0 0 0 Michele V McNeill PharmD 1.0 X 0 0 0 Richard H Metzner 1.0 X 0 0 0 Edward Milstein 1.0 X 0 0 0 CINDY RACHOFSKY 1.0 X 0 0 0 Vincent A Roberti 1.0 X 0 0 0 Alan D Schwartz 1.0 X 0 0 0 Kevin Wendle 1.0 X 0 0 0 regan hoffman 1.0 X 0 0 0 MERVYN F SILVERMAN MDMPH 1.0 X 0 0 0 Kevin Frost 40.0 X 294100 0 32217 John F Logan JD PhD 40.0 X 179424 0 20308 Rowena Johnston 40.0 X 138712 0 17571 Bradley Jensen 40.0 X 192220 0 34529 edward donnelly 40.0 X 118397 0 15917 annette sohn 40.0 X 161626 0 12430 Eric Muscatell 40.0 X 140535 0 18238 Andrew McInness 40.0 X 123398 0 32215 gregory borroff 40.0 X 138354 0 6955 michael cowing 40.0 X 122269 0 16403 anthony ancona 40.0 X 131683 0 6893 joshua lamont 40.0 X 174397 0 7262 Jerome J Radwin 40.0 X 300000 0 0 Jeff Smith 40.0 X 119330 0 8122 2334445 0 229060 16 true true false aab production 32 west 25th street suite 300 NEW YORK NY 10011 event production 322200 grant thornton llp 1901 w meyers road suite 455 OAKBROOK TERRACE IL 60181 accounting & audit 152788 downey mcgrath group inc 27 west 24th street suite 900 NEW YORK NY 10010 program tech support 150000 Global Health Strategies 27 W 27TH STREET SUITE 900 NEW YORK NY 10010 scientific consult 135000 Global Health Institute 3403 rolling court CHEVY CHASE MD 20815 consulting 120000 7 445702 7838799 5959900 7720658 5373 21965059 0 516589 516589 0 150248 150248 4604120 4614005 -9885 -9885 -9885 8276910 7838799 5987021 2289889 2289889 0 438392 16763 421630 421630 LIST RENTALS 900099 27804 27804 MISCELLANEOUS INCOME 900099 67 67 27871 25361401 3396342 1522428 1522428 0 3081771 3081771 0 2030119 1269296 448317 312506 0 4275896 2925002 309822 1041072 245872 163242 20112 62518 745819 534066 89478 122275 438058 281980 53654 102424 0 98505 91169 3729 3607 164947 164947 120602 120602 483987 483987 62734 62734 1023998 663820 92709 267469 90427 86960 373 3094 67603 40263 8108 19232 0 0 1157448 782157 175145 200146 766208 501385 7886 256937 0 840351 749606 7870 82875 0 0 251647 170299 38134 43214 163288 110343 24709 28236 PROGRAM MATERIALS 2285977 2285977 0 0 BAD DEBT EXPENSE 1280142 865069 193711 221362 POSTAGE & SHIPPING 687829 285635 3356 398838 PRINTING 553508 193674 0 359834 PROGRAM TECHNICAL SUPPORT 471530 471530 0 0 843342 381245 250423 211674 23754036 17577519 1955217 4221300 X 1019556 374578 0 644978 861762 5446802 9541547 5963522 6732230 5825604 1620968 2471863 94415 144295 376156 556359 2977785 2506228 636526 471557 12420043 13623286 1224169 1301141 33507816 35804429 1712165 1644227 1255912 573764 1877071 2679898 429309 340774 5274457 5238663 X 15502757 18926218 12411691 11312379 318911 327169 28233359 30565766 33507816 35804429 X false true true X true true X 18200457 22038265 30491706 20760601 22553697 114044726 18200457 22038265 30491706 20760601 22553697 114044726 7908448 106136278 670429 822092 842799 643473 668573 3647366 21009 38835 4819221 117005 2317760 7313830 125005922 1052722 0.84905 0.87094 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false true false false false false true 211592 false false 211592 false false Lobbying Expenses Part II-B (1B) VP FOR POLICY AND DEPUTY BOTH SPENT STAFF TIME ON LEGISLATIVE ADVOCACY. THE AMOUNT OF EXPENDITURES RELATED TO THIS LINE ITEM TOTALS $11,413 (AND IS INCLUDED IN THE $211,592 REPORTED ON LINE 1(G)). (1G) WE DEVELOPED ISSUE BRIEFS ON THE GLOBAL AIDS RESPONSE, YOUTH AND HIV, AND US GOVERNMENT INVESTMENTS IN AIDS AND HEALTH GENERALLY. THESE ISSUE BRIEFS ARE SENT TO CAPITOL HILL OFFICES; WE MEET REGULARLY WITH STAFF TO MEMBERS OF CONGRESS AND THE ADMINISTRATION. WE HELD BRIEFINGS ON CAPITOL HILL ON HIV AND YOUTH, AS WELL AS AIDS RESEARCH. WE ALSO HELD A FORUM ON GLOBAL MSM/HIV ISSUES IN WASHINGTON, DC. AMFAR USES THE BRIEFINGS AS AN EDUCATIONAL TOOL. 144295 X Donated Items, Inventory etc. true 516826 8258 35999 561083 470065 9378 37383 516826 0.64670 0.35330 false false 781297 309740 471557 234641 234641 0 1961847 1961847 0 471557 0 MISCELLANEOUS 340774 340774 25361401 23754036 1607365 481762 243280 725042 2332407 26244056 481762 157613 243280 882655 25361401 25361401 23911649 157613 157613 23754036 23754036 Endowments Part V, Line 4 AMFAR's endowment fund is intended to fund the various general research programs the organization sponsors. Schedule D, Part III, Line 4 AMFAR holds various items of jewelry, photographs and other items of artistic value that have been donated to the organization for sale at special events. The organization has maintained these items in inventory for a few years and is in the process of selling them. Reclassifications In September 2010, New York State passed its own version of UPMIFA ("NYPMIFA") that applies to amfar's fiscal 2010 financial statements. Accordingly, certain amounts in the 2009 financial statements and footnote disclosures with respect to the organization's endowment have been reclassified to conform with the 2010 financial statement presentation. AMFAR has adjusted its Schedule d, Part V endowment disclosure to conform to the audited financial statement presentation. Certain amounts in the 2009 financial statements and footnote disclosures have been reclassified to conform with the 2010 financial statement presentation. FIN 48 amfAR adopted new guidance that clarifies the accounting for uncertainty in tax positions taken or expected to be taken in a tax return, including issues relating to financial statement recognition and guidance on measurement, classification, interest and penalties, and disclosure. This standard had no material impact on the accompanying financial statements. The tax years ended 2007, 2008, and 2009 are still open to audit for both federal and state purposes. amfAR has processes presently in place to ensure the maintenance of its tax-exempt status; to identify and report unrelated income; to determine its filing and tax obligations in jurisdictions for which it has nexus; and to identify and evaluate other matters that may be considered tax positions. reconciliation part XI, Line 8 change in value of beneficial interest in third party trust: $243,280 part XII, Line 2d change in value of beneficial interest in third party trust: $243,280 true Central America and the Caribbean 0 0 Grantmaking N/A 105000 Russia and the Newly Independent States 0 0 Grantmaking N/A 114560 East Asia and the Pacific 1 20 Grantmaking N/A 2621149 North America 0 0 Fundraising N/A 114339 East Asia and the Pacific 1 20 Program Services Therapeutics Research 1692080 Europe (Including Iceland and Greenland) 0 0 Grantmaking N/A 363851 Europe (Including Iceland and Greenland) 0 0 Fundraising N/A 2584923 Middle East and North Africa 0 0 Fundraising N/A 639651 South America 0 0 Grantmaking N/A 143409 South Asia 0 0 Grantmaking N/A 56662 Sub-Saharan Africa 0 0 Grantmaking N/A 171681 2 40 8607305 Caribbean/Central Americ MSM Initiative 15000 wire transfe Caribbean/Central Americ MSM Initiative 30000 wire transfe Caribbean/Central Americ MSM Initiative 15000 wire transfe Caribbean/Central Americ MSM Initiative 15000 wire transfe Caribbean/Central Americ MSM Initiative 15000 wire transfe Caribbean/Central Americ MSM Initiative 15000 wire transfe East Asia/Pacific Social/Behavioral Research 15702 wire transfe East Asia/Pacific MSM Initiative 15000 wire transfe East Asia/Pacific MSM Initiative 29998 wire transfe East Asia/Pacific MSM Initiative 15000 wire transfe East Asia/Pacific MSM Initiative 15000 wire transfe East Asia/Pacific MSM Initiative 14975 wire transfe East Asia/Pacific MSM Initiative 29728 wire transfe East Asia/Pacific MSM Initiative 15000 wire transfe East Asia/Pacific MSM Initiative 15980 wire transfe East Asia/Pacific TREAT Asia 13700 wire transfe East Asia/Pacific TREAT Asia 16500 wire transfe East Asia/Pacific TREAT Asia 16500 wire transfe East Asia/Pacific TREAT Asia 16500 wire transfe East Asia/Pacific TREAT Asia 16500 wire transfe East Asia/Pacific TREAT Asia 16500 wire transfe East Asia/Pacific TREAT Asia 20500 wire transfe East Asia/Pacific TREAT Asia 16500 wire transfe East Asia/Pacific TREAT Asia 7500 wire transfe East Asia/Pacific TREAT Asia 7500 wire transfe East Asia/Pacific TREAT Asia 6975 wire transfe East Asia/Pacific TREAT Asia 7350 wire transfe East Asia/Pacific TREAT Asia 7500 wire transfe East Asia/Pacific TREAT Asia 6075 wire transfe East Asia/Pacific TREAT Asia 7500 wire transfe East Asia/Pacific TREAT Asia 7500 wire transfe East Asia/Pacific TREAT Asia 6000 wire transfe East Asia/Pacific TREAT Asia 7500 wire transfe East Asia/Pacific TREAT Asia 14543 wire transfe East Asia/Pacific TREAT Asia 15000 wire transfe East Asia/Pacific TREAT Asia 15000 wire transfe East Asia/Pacific TREAT Asia 15000 wire transfe East Asia/Pacific TREAT Asia 15000 wire transfe East Asia/Pacific TREAT Asia 14950 wire transfe East Asia/Pacific TREAT Asia 15000 wire transfe East Asia/Pacific TREAT Asia 14018 wire transfe East Asia/Pacific TREAT Asia 15000 wire transfe East Asia/Pacific TREAT Asia 15000 wire transfe East Asia/Pacific TREAT Asia 15000 wire transfe East Asia/Pacific TREAT Asia 15000 wire transfe East Asia/Pacific TREAT Asia 15000 wire transfe East Asia/Pacific TREAT Asia 15000 wire transfe East Asia/Pacific TREAT Asia 14999 wire transfe East Asia/Pacific TREAT Asia 5625 wire transfe East Asia/Pacific TREAT Asia 5625 wire transfe East Asia/Pacific TREAT Asia 5625 wire transfe East Asia/Pacific TREAT Asia 5625 wire transfe East Asia/Pacific TREAT Asia 14999 wire transfe East Asia/Pacific TREAT Asia 14999 wire transfe East Asia/Pacific TREAT Asia 11250 wire transfe East Asia/Pacific TREAT Asia 11250 wire transfe East Asia/Pacific TREAT Asia 11250 wire transfe East Asia/Pacific TREAT Asia 34875 wire transfe East Asia/Pacific TREAT Asia 277990 wire transfe East Asia/Pacific TREAT Asia 119666 wire transfe East Asia/Pacific TREAT Asia 187285 wire transfe East Asia/Pacific TREAT Asia 157341 wire transfe East Asia/Pacific TREAT Asia 49114 wire transfe East Asia/Pacific TREAT Asia 60000 wire transfe East Asia/Pacific TREAT Asia 72917 wire transfe East Asia/Pacific TREAT Asia 47176 wire transfe East Asia/Pacific TREAT Asia 47176 wire transfe East Asia/Pacific TREAT Asia 49050 wire transfe East Asia/Pacific TREAT Asia 48320 wire transfe East Asia/Pacific TREAT Asia 61650 wire transfe East Asia/Pacific TREAT Asia 49050 wire transfe East Asia/Pacific TREAT Asia 65400 wire transfe East Asia/Pacific TREAT Asia 48320 wire transfe East Asia/Pacific TREAT Asia 49050 wire transfe East Asia/Pacific TREAT Asia 79290 wire transfe East Asia/Pacific TREAT Asia 52000 wire transfe East Asia/Pacific TREAT Asia 6560 wire transfe East Asia/Pacific TREAT Asia 6480 wire transfe East Asia/Pacific TREAT Asia 37320 wire transfe East Asia/Pacific TREAT Asia 5001 wire transfe East Asia/Pacific TREAT Asia 5001 wire transfe East Asia/Pacific TREAT Asia 12501 wire transfe East Asia/Pacific TREAT Asia 47808 wire transfe East Asia/Pacific TREAT Asia 53577 wire transfe East Asia/Pacific TREAT Asia 10584 wire transfe East Asia/Pacific TREAT Asia 16918 wire transfe East Asia/Pacific TREAT Asia 58740 wire transfe East Asia/Pacific TREAT Asia 9990 wire transfe East Asia/Pacific TREAT Asia 10000 wire transfe East Asia/Pacific TREAT Asia 10000 wire transfe East Asia/Pacific TREAT Asia 10000 wire transfe Europe Social/Behavioral Research 15614 wire transfe Europe Basic Research 15626 wire transfe Europe Clinical Research 12000 wire transfe Europe Basic Research 10398 wire transfe Europe Basic Research 62501 wire transfe Europe Basic Research 57452 wire transfe Europe Basic Research 150000 wire transfe Europe MSM Initiative 9000 wire transfe Europe MSM Initiative 14980 wire transfe Europe TREAT Asia 15000 wire transfe Russia/Newly Independent MSM Initiative 14560 wire transfe Russia/Newly Independent MSM Initiative 10000 wire transfe Russia/Newly Independent MSM Initiative 15000 wire transfe Russia/Newly Independent MSM Initiative 30000 wire transfe Russia/Newly Independent MSM Initiative 15000 wire transfe Russia/Newly Independent MSM Initiative 30000 wire transfe South America MSM Initiative 9500 wire transfe South America MSM Initiative 10000 wire transfe South America MSM Initiative 13900 wire transfe South America MSM Initiative 15000 wire transfe South America MSM Initiative 12716 wire transfe South America MSM Initiative 15000 wire transfe South America MSM Initiative 14993 wire transfe South America MSM Initiative 7300 wire transfe South America MSM Initiative 15000 wire transfe South America MSM Initiative 15000 wire transfe South America MSM Initiative 15000 wire transfe South Asia TREAT Asia 16500 wire transfe South Asia TREAT Asia 11250 wire transfe South Asia TREAT Asia 11250 wire transfe South Asia TREAT Asia 14999 wire transfe Sub-Saharan Africa Social/Behavioral Research 57054 wire transfe Sub-Saharan Africa MSM Initiative 15000 wire transfe Sub-Saharan Africa MSM Initiative 10077 wire transfe Sub-Saharan Africa MSM Initiative 13800 wire transfe Sub-Saharan Africa MSM Initiative 15000 wire transfe Sub-Saharan Africa MSM Initiative 15000 wire transfe Sub-Saharan Africa MSM Initiative 15000 wire transfe Sub-Saharan Africa MSM Initiative 15000 wire transfe Sub-Saharan Africa MSM Initiative 15750 wire transfe 131 0 Foreign Activities Part I, Line 2 International organizations are recommended for funding based upon the results of community-based peer review and/or program staff assessment of proposal merit and organization capacity to undertake proposed projects that are CHARITABLE in purpose. Pre-award due-diligence for new international grantees includes review of organization documents and registrations to verify that the organization operates for a CHARITABLE purpose and that basic capacity for project oversight and governance has been established. All international grantees are required to report semi-annually on project progress and expenditures; continued reporting is required until such time as grant funds are expended in full. Reports are reviewed by administrative and program staff. Additional oversight is provided as necessary by means of ongoing, informal contact with sites regarding progress and technical issues and site visits where feasible. International research grant recipients submit an interim and a final progress reporting addition to expenditures reports due following the ends of the 2nd, 3rd and final quarters of the performance period. foreign activities Part I, Line 3, Column D The Foundation for AIDS Research conducts many of its grant-making program services (see Part III of Form 990) in U.S. and foreign jurisdictions. In column D, the organization has reported the basic program these grants support; please refer to Part III for more information about these programs/initiatives. Foreign Activities - Status of Grantees The Foundation for Aids Research supports many non-U.S. organizations in the fight against AIDS and HIV-related diseases. For purposes of Schedule F, Part II, Line 2 - all 131 charities supported are presumed to be the equivalent of U.S. charities. X X X X X X true aab productions Fundraising Event/Prod false 9350226 322200 9028026 john mini consulting inc direct mail false 1574907 117500 1457407 livet reichard company inc event production false 3692476 102375 3590101 public interest communications tele marketing false 99905 59692 40213 sgr consulting event production false 417170 42000 375170 share group inc tele marketing false 5387 0 5387 telefund tele marketing false 153863 59921 93942 15293934 703688 14590246 AL AK AZ AR CA CO CT DC FL GA HI IL KS KY LA ME MD MA MI MN MS MO NH NJ NM NY NC ND OH OK OR PA RI SC TN TX UT VA WA WV WI cannes 6046069 2265572 3780497 394093 1549524 dallas 3759396 1084670 2674726 37917 2077865 18 6310244 4488557 1821687 66823 1860799 16115709 7838799 8276910 498833 5488188 5987021 2289889 true Dana Farber Cancer Institute 44 Binney St Boston MA 02115 042263040 501(c)(3) 123752 Basic Research The University of Pennsylvania School of Medicine 3451 Walnut St Philadelphia PA 19104 231352685 501(c)(3) 15626 Basic Research Aaron Diamond AIDS Research Center 455 First Avenue 7th Floor New York NY 10016 133540234 501(c)(3) 15626 Basic Research University of Missouri-Columbia 310 Jesse Hall Columbia MO 65211 436003859 501(c)(3) 15626 Basic Research University of Washington 1100 Fairview Avenue N D3-100 Seattle WA 98109 916001537 501(c)(3) 15626 Basic Research The J David Gladstone Institute 1650 Owen Street San Francisco CA 94158 237203666 501(c)(3) 32319 Basic Research Yale University 47 College Street New Haven CT 06520 060649730 501(c)(3) 40680 Social/Behavioral Univ of North Carolina at Chapel Hill 104 Airport Drive Suite 2200 CB 1 Chapel Hill NC 27599 566001393 501(c)(3) 63483 Basic Research University of Utah 75 S 2000 E Second Fl Salt Lake City UT 84112 187600525 501(c)(3) 62501 Basic Research University of Texas at Austin PO Box 7726 Austin TX 78712 746000203 501(c)(3) 30000 Basic Research The University of Michigan 3003 South State Street Ann Arbor MI 48109 386006309 501(c)(3) 30000 Basic Research Washington University School of Medicine 660 S Euclid Ave St Louis MO 63110 143065361 501(c)(3) 30000 Basic Research University of Utah 75 S 2000 E Second Fl Salt Lake City UT 84112 187600525 501(c)(3) 62501 Basic Research Yale University School of Medicine 47 College Street New Haven CT 06520 060646973 501(c)(3) 62501 Basic Research Virginia Commonwealth University PO Box 980568 Richmond VA 232980568 546001758 501(c)(3) 49957 Social/Behavioral San Francisco Department of Health 1380 Howard Street 5th Fl San Francisco CA 94102 946000417 501(c)(3) 25606 Social/Behavioral Weill Medical College of Cornell Univ 1300 York Avenue New York NY 10065 131623978 501(c)(3) 46872 Basic Research UT Southwestern Medical Center 5323 Harry Hines Blvd Dallas TX 753909105 175600286 501(c)(3) 46872 Basic Research NYU School of Medicine 550 First Avenue New York NY 10016 113556230 501(c)(3) 46872 Basic Research University of California-Davis One Shields Avenue Davis CA 95616 946036494 501(c)(3) 36456 Basic Research California Institute of Technology 1200 East California Blvd Pasadena CA 91106 951643307 501(c)(3) 36456 PreClinical Research University of Minnesota 200 Oak Street SE Minneapolis MN 554552070 416007513 501(c)(3) 36456 Basic Research University of Florida 1600 SW Archer Rd ARB R1-252 Gainesville FL 32610 592729133 501(c)(3) 70000 Basic Research University of WashingtonFHCRC 1100 Fairview Avenue N D3-100 Seattle WA 98109 916001537 501(c)(3) 70000 Basic Research University of Texas Southwestern 5323 Harry Hines Blvd L4256 Dallas TX 75390 175600286 501(c)(3) 70000 Basic Research Albert Einstein College of Medicine 1300 Morris Park Avenue Bronx NY 10461 132937352 501(c)(3) 46667 Basic Research San Francisco AIDS Foundation 995 Market Street Suite 200 San Francisco CA 94103 942927405 501(c)(3) 5500 Research/Conference Support The Regents of the University of California San Fr 333 California Street Suite 315 San Francisco CA 94110 946036493 501(c)(3) 150000 Basic Research Johns Hopkins University 733 N Broadway Suite 117 Broadwa Baltimore MD 21205 520595110 501(c)(3) 150000 Basic Research Beckman Research Institue of City of Hope 1500 E Duarte Road Duarte CA 910103000 953432210 501(c)(3) 50000 Basic Research NYU School of Medicine 550 First Avenue New York NY 10016 113556230 501(c)(3) 11000 Social/Behavioral Montefiore Medical Center 111 E 210th St Bronx NY 10467 131740114 501(c)(3) 11000 Policy Research University of California Los Angeles 11000 Kinross Avenue Ste 102 Los Angeles CA 900951406 956006143 501(c)(3) 25000 Research/Conference Support Global Forum on MSM and HIV 611 S Kingsley Drive Los Angeles CA 90005 953842506 501(c)(3) 10000 MSM Initiative The Fenway Institute 1340 Boylston Street Boston MA 02115 425105640 501(c)(3) 10000 MSM Initiative Beth Israel Medical Center First Avenue at 18th Street New York NY 10003 135564934 501(c)(3) 115000 Policy Research 36 0 Grants and Assistance Part I, Line 2 All U.S. 501(c)(3) grant and award recipients are required to report at least once on activities supported with amfAR funds; all U.S. research grant recipients (which include 501(c)(3) organizations and other nonprofit entities such as state universities) are required to submit an interim and a final progress report in addition to expenditure reports due following the ends of the 2nd, 3rd and final quarters of the performance periods. Reports are reviewed by grant administration and program staff prior to payment and/or closeout. X X X X X true true false false false false false false false Jerome J Radwin 0 0 0 0 300000 0 0 0 0 0 300000 0 0 0 Kevin Frost 294100 0 0 0 0 0 24650 0 7567 0 326317 0 0 0 John F Logan JD PhD 179424 0 0 0 0 0 12740 0 7568 0 199732 0 0 0 Rowena Johnston 138712 0 0 0 0 0 9842 0 7729 0 156283 0 0 0 Bradley Jensen 192220 0 0 0 0 0 10238 0 24291 0 226749 0 0 0 annette sohn 161626 0 0 0 0 0 8955 0 3475 0 174056 0 0 0 joshua lamont 146897 0 0 0 27500 0 0 0 7262 0 181659 0 0 0 Eric Muscatell 140535 0 0 0 0 0 10025 0 8213 0 158773 0 0 0 Jeff Smith 89330 0 0 0 30000 0 0 0 8122 0 127452 0 0 0 Andrew McInness 123398 0 0 0 0 0 8780 0 23435 0 155613 0 0 0 Compensation Part I, Line 4 Chief Executive Officer, Kevin Frost, participated in a supplemental nonqualified retirement plan; however, he did not receive a distribution in 2009. Jerome J. Radwin received severance in calendar year 2009 totaling $300,000. Joshua Lamont, Vice President of Public Information, separated from service as of November 13, 2009. For purposes of the Form 990, Mr. Lamont is a current officer. He received a severance payment totaling $27,500 in 2009. This severance payment is reflected in Schedule J, Column (b)(iii). Jeffrey Smith, Director of the Treat Asia Program, separated from service as of August 31, 2009. For purposes of the Form 990, Mr. Smith is a former officer. He received a severance payment totaling $30,000 in 2009. This severance payment is reflected in Schedule J, Column (b)(iii). X 5 5373 sales price false false false Program Service Accomplishments Part III, Line 4a-4d Line 4a RESEARCH amfAR supports research projects that explore novel approaches to scientifically sound but untested hypotheses in all areas of research on HIV/AIDS, funding goal-oriented studies that often lack the preliminary data required for support from traditional grant-makers. The Foundation plays a vital role in HIV/AIDS research, identifying critical gaps in knowledge and providing essential seed money that enables grantees and fellows to test the merits of new concepts or technologies that subsequently can be validated through large-scale studies, such as those funded by the National Institutes of Health. amfAR fellowships allow talented young investigators to conduct original investigations under the guidance of experienced scientists, helping to ensure the long-term vitality of AIDS research. New Grants and Fellowships Grants and fellowships are awarded through a rigorous process of peer review by a team of independent HIV/AIDS experts drawn largely from the volunteer scientists on amfAR's Scientific Advisory Committee. Guided by its scientific advisors and with the approval of its board of trustees, amfAR pursues a strategic research plan that focuses on the treatment, prevention, and cure of HIV/AIDS. In 2010, amfAR awarded 17 new grants and fellowships totaling $2,518,674. Three researchers received Mathilde Krim Fellowships in Basic Biomedical Research, an initiative that provides funding for exceptional young researchers who are new to the field of HIV/AIDS research. The initiative has already achieved spectacular results, including numerous published studies in major scientific journals. The 2010 Krim Fellows-each of whom received $125,000-are conducting studies of viral resistance to antiretroviral drugs, the ways in which HIV binds to cell proteins, and how HIV overcomes the body's natural defenses. Among the 2010 fellows is Thomas Gramberg, Ph.D., of the NYU School of Medicine, whose research aims to understand how HIV is able to overcome the natural antiviral defenses of cells. He is characterizing proteins in cells that would normally have antiviral effects but are overcome by two proteins made by HIV, and pinpointing which part of the replication cycle is targeted. These insights may provide new targets for antiretroviral drug development. Two researchers who were among the inaugural group of Krim Fellows in January 2008 received Phase II funding totaling $142,675 to continue their research. Rogier Sanders, Ph.D., of the Academic Medical Center, University of Amsterdam, has been working to modify the envelope protein surrounding HIV with the goal of improving potential vaccines based on this protein. In phase II, he will characterize the antibody responses induced by these "evolved" envelope proteins. amfAR also announced its first ever awards for gene therapy research- three grants and three fellowships totaling $735,000. The funded projects represent a broad range of gene therapy interventions aimed at blocking HIV infection and eradicating the virus. Keith Jerome, M.D., Ph.D., is using homing endonucleases-a type of molecular scissors-to lethally cut up HIV's DNA. This method of attack can target HIV even when it is inactive-unlike anti-HIV drugs, which target the virus only when it reproduces-and thus may be a means of eradicating HIV from the body completely. Placing the search for a cure for HIV/AIDS at the center of its research efforts, the Foundation launched the amfAR Research Consortium on HIV Eradication (ARCHE) in May 2010. The first round of funding, totaling $1.2 million, went to four collaborative teams of researchers working in three areas considered central to HIV eradication: the search for a sterilizing cure to eliminate HIV from the body; the search for a functional cure to suppress the virus without treatment; and the characterization of viral reservoirs, which present an obstacle to a cure. Among these researchers is Robert Siliciano, M.D., Ph.D., of Johns Hopkins University, collaborating with Janice Clements, Ph.D. They are studying drugs that have already been approved to treat other conditions, with the aim of testing whether these agents might reduce or even eradicate the virus in the body or the number of cells harboring latent HIV. If successful, these studies could point the way to strategies that could shorten the development time of drugs to cure HIV. In 2010, amfAR also worked with the New York HIV Research Centers Consortium to fund two inaugural awards totaling $65,999 for a new research initiative aimed at shaping health policy and treatment programs across the state. Dr. Carolyn Chu of Montefiore Medical Center, is studying health service delivery and treatment outcomes of HIV patients at primary care clinics in the Bronx; and Dr. Susan Abramowitz of NYU School of Medicine, is evaluating interventions for HIV-infected adolescents. Published Research Research studies make the greatest impact on the AIDS field and on the broader scientific community when they are published in scientific journals. In the past year, at least 34 scientific publications resulted from amfAR-funded research. These covered current and past targeted areas of research interest. Keys to a New Anti-HIV Compound Our ability to control the growth of HIV and block its attack on immune cells is based on having a large repertoire of drugs belonging to different drug classes, each of which slows the life cycle of the virus at different stages of growth. Dr. Bruno Marchand, who received a Krim Fellowship from amfAR in 2009, reports in the Journal of Biological Chemistry on the mechanism of action of a new type of reverse transcriptase (RT) inhibitor, known as EFdA, which has the potential to become a new anti-HIV drug. EFdA is closely related to the RT inhibitors that became the first FDA-approved HIV medications, but it has greater potency and a different mechanism of action. Studying how this new inhibitor works may aid in the development of a new and more effective weapon in the anti-HIV arsenal. Reducing HIV Growth to Zero Could intensifying anti-HIV treatment slow virus growth rates even further than current highly active antiretroviral therapy (HAART) regimens, or even eradicate the virus? amfAR-funded researcher Dr. Sarah Palmer of the Swedish Institute for Infectious Disease Control, with colleagues from other institutions, explored this question in an article in Nature Medicine. The researchers studied patients whose virus levels were already well controlled on standard HAART but who had extremely low but measurable amounts of virus in their blood. The scientists added another drug, raltegravir, to their regimen, and studied patients' DNA for signs of accumulating virus that was stopped by the additional drug. Their findings suggested that although most patients on HAART do not show signs of viral growth, one-third of the patients studied had ongoing viral growth, which was impeded by the addition of raltegravir to their treatment regimen. HIV, HAART, and the Kidneys Mild kidney disease is seen in up to one-third of HIV-positive individuals, but the prevalence of more significant chronic kidney disease is expected to increase as the HIV-positive population ages. Writing in AIDS, amfAR grantee Dr. Steven Deeks and his colleagues at the University of California, San Francisco, reported on the relationships between HIV, HAART, and the risk of developing kidney disease. They found that HAART slowed the loss of kidney function, but that loss of function continued nonetheless and accelerated in patients on HAART who experienced intermittent rises in viral load. This study was part of an ongoing trial known as SCOPE-Study of the Consequences of the Protease Inhibitor Era-that examines the impact of anti-HIV drugs as people with HIV live longer. New Targeted RFP amfAR issued a request for proposals (RFP) in September 2010 for studies exploring the mechanisms whereby HIV persists; the chronic nature of viral reservoirs and latency; and barriers to the eradication of HIV, with the potential goal of ultimately eliminating HIV infection. Think Tanks and Conferences Following the announcement of first-round funding for amfAR's cure consortium, ARCHE, researchers from the four teams met at amfAR's offices in June 2010 to discuss their research and explore ideas for future collaborations among the consortium members. Program Service Accomplishments Part III, Line 4a-4d Line 4b TREAT ASIA amfAR's TREAT Asia program (Therapeutics Research, Education, and AIDS Training in Asia) involves a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of HIV/AIDS treatments across Asia and the Pacific. The TREAT Asia Network encompasses 23 adult and 20 pediatric sites throughout the region, which collaborate on a variety of projects. Eight papers based on the network's research were published in U.S. and international scientific journals in 2010. TREAT Asia HIV Observational Database (TAHOD) TREAT Asia pioneered the region's first adult observational database for HIV/AIDS, which now includes anonymous data collected from more than 6,400 patients at 23 clinical sites in 13 countries. The information gathered and analyzed through the database informs the development of more effective research and treatment programs, and helps define treatment standards specific to HIV/AIDS in Asia. TREAT Asia Pediatric Network Representing more than 5,000 HIV-positive children in Asia, TREAT Asia's Pediatric Network includes 20 sites in seven countries; these sites share information and best practices in an effort to improve the quality of pediatric care in the region. The TREAT Asia Pediatric HIV Observational Database (TApHOD) was modeled on the adult TAHOD program, and includes data from approximately 3,600 pediatric patients at 16 clinical sites in Cambodia, India, Indonesia, Malaysia, Thailand, and Vietnam. TREAT Asia Studies to Evaluate Resistance (TASER) TREAT Asia has worked for the past five years with organizations in the Netherlands to build capacity to monitor the emergence and spread of HIV drug resistance in Asia and Africa. As more countries expand access to antiretroviral therapy, monitoring resistance to first-line treatments is essential, particularly in countries where access to second-line drugs is limited. The TREAT Asia Studies to Evaluate Resistance (TASER) made significant progress during 2010. For its monitoring study, which monitors the emergence of drug-resistant HIV in infected patients, nine clinical centers have now enrolled more than 1,500 patients in Hong Kong, Indonesia, Malaysia, the Philippines, and Thailand. For its surveillance study, which evaluates the spread of drug-resistant virus among newly infected patients, two clinical centers in Thailand and one in Hong Kong enrolled a total of 87 patients in 2010. As part of TASER's work, TREAT Asia also runs a laboratory quality assurance program to ensure the accuracy and consistency of the HIV genetic analysis required to determine if HIV has become resistant to drugs. International AIDS Database TREAT Asia manages the Asia-Pacific section of the International Epidemiologic Databases to Evaluate AIDS (IeDEA), a global collaboration established by the U.S. National Institute of Allergy and Infectious Diseases. To support IeDEA, TREAT Asia is contributing anonymous data from approximately 13,400 patients at 61 clinical centers at 55 institutions in 15 countries within Asia and Australia. Exploring Links Between HIV and Cancer Among HIV-positive men who have sex with men (MSM), the risk of anal cancer is twice the level of those who are HIV negative, but little research has been done on this issue in Asia. With funding from IeDEA, in December 2009 TREAT Asia began the second phase of an innovative research study exploring the links between HIV and anal cancer and looking at cancer biomarkers in an attempt to better identify MSM with pre-cancerous anal lesions. Building Research Capacity TREAT Asia has implemented a research education program to help network members strengthen their skills in conducting clinical research and to boost the overall quality of care in the region. The program, supported by the Australian Agency for International Development, provides training for researchers and clinicians in Cambodia, China, Indonesia, the Philippines, Papua New Guinea, and Vietnam. In late 2009 and early 2010, TREAT Asia organized several workshops and training sessions including a training on good clinical research practice, held in Jakarta, Indonesia, in October 2009; a two-part training in clinical epidemiology for pediatric specialists in Vietnam, held in November 2009 and February 2010 in Ho Chi Minh City; and two English-language scientific writing workshops, held in China in January and June 2010. The Purple Sky Network TREAT Asia serves as regional coordinating secretariat for the Purple Sky Network, which works in the Greater Mekong Sub-region to address the rise of HIV among MSM. The network, which brings together more than 80 organizations in Cambodia, Laos, Myanmar, Thailand, Vietnam, and China's Yunnan and Guangxi provinces, created a formal governance structure and established a set of priorities for its ongoing work. Advocacy efforts that reduce stigma and discrimination against MSM and transgender people will cut across the diverse social and political settings within the region. Building Community Treatment Literacy and Promoting Advocacy for Treatment Access Communicating treatment information about a disease as complex as HIV/AIDS can be daunting, but patients' lives depend on it. TREAT Asia works closely with local and regional groups to support treatment literacy activities in China, where it helps support the award-winning AIDS Care China program; and in Cambodia, where it provides assistance to the Cambodian Community of Positive Women. TREAT Asia also began a new partnership with UNAIDS, the Asia-Pacific Network of People Living with HIV/AIDS, the International Treatment Preparedness Coalition, and the Mdecins Sans Frontires Access Campaign. Through the newly formed Asia Treatment Working Group, TREAT Asia will be part of a platform for promoting treatment access and higher quality HIV healthcare within the region. AIDS Research Information for Asia In 2010, TREAT Asia continued to publish lay-language articles about topical new research in the fields of prevention, treatment, and basic science. The goal of these articles is to explain HIV/AIDS research advances for people living with HIV/AIDS and their families, communities, and caregivers across Asia. The articles appear in the TREAT Asia Report and on TREAT Asia's website, www.treatasia.org, where they are also available as PDFs in a variety of Asian languages including Bahasa Indonesia, Burmese, Chinese, Khmer, and Thai. XVIII International AIDS Conference TREAT Asia was well represented at the XVIII International AIDS Conference, held in July 2010 in Vienna, Austria, where several network members and partners presented their research findings. In addition, TREAT Asia was a scientific co-sponsor of the 2nd International Workshop on HIV Pediatrics, which preceded the conference. 13th Bangkok Symposium on HIV Medicine amfAR continued its support of this annual regional symposium, which was held in January 2010 and was organized by HIV-NAT, a TREAT Asia network site. Program Service Accomplishments Part III, Line 4a-4d Line 4c EDUCATION AND INFORMATION amfAR seeks to translate and disseminate information on important AIDS-related research, treatment, prevention, and policy issues for diverse audiences and to stimulate broad awareness of the need for better treatment and prevention methods. amfAR also publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policy makers in communicating the need for continued research to develop new methods of prevention, treatment, and, ultimately, a cure for AIDS. Educational Materials amfAR produces a range of periodicals in both print and electronic formats, including its newsletter Innovations, published twice a year and distributed to more than 40,000 people; the TREAT Asia Report, published and distributed three times a year to more than 4,000 readers in the international health community; and a monthly e-mail newsletter distributed to more than 40,000 people. The Foundation's website features news, interviews, and original articles covering science, policy, the global epidemic, and amfAR programs and activities. amfAR also creates and distributes program reports, press releases, and updates on major HIV/AIDS issues, and conducts public service advertising campaigns that have been instrumental in educating policy makers, healthcare professionals, people with HIV/AIDS, and the general public. Media Outreach amfAR continued to work closely with the media to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of AIDS press coverage. Articles and reports involving amfAR-many of which included interviews with amfAR spokespeople-were carried in numerous media outlets, including the Wall Street Journal, The Financial Times, the New York Times, the Washington Post, Nature, the Associated Press, Reuters, and Bloomberg News. On December 1, 2009-World AIDS Day-CNN's American Morning featured a profile of amfAR Chairman Kenneth Cole, focusing on his AIDS activism and longtime involvement with amfAR. Also on World AIDS Day, amfAR was a co-sponsor of the global Light for Rights campaign, which focused attention on the need to protect the human rights of those living with HIV. amfAR's public awareness efforts are greatly enhanced by the committed support of public figures who lend their voices and donate their time, talents, and resources to help sustain the Foundation's mission. amfAR is profoundly grateful for the continuing steadfast support of Founding International Chairman Elizabeth Taylor and Global Fundraising Chairman Sharon Stone. In 2010, these supporters included amfAR Ambassadors Cheyenne Jackson, Milla Jovovich, Liza Minnelli, and Michelle Yeoh, as well as Alan Cumming, Whoopi Goldberg, Kylie Minogue, Vanessa Redgrave, Maggie Rizer, Martin Sheen, Meryl Streep, and Stanley Tucci. Program Service Accomplishments Part III, Line 4a-4d THE MSM INITIATIVE amfAR's MSM Initiative was launched in 2007 to respond to the alarmingly high rates of HIV among MSM, a group that in low- and middle-income countries is on average 19 times more likely to be infected than the general population. Stigma, discrimination, and legal prohibitions have fueled the spread of the epidemic among MSM, most of whom do not have access to HIV prevention, treatment, and care services. The MSM Initiative aims to reduce the spread and impact of HIV infection among MSM in resource-limited countries by providing support to grassroots groups through its community awards program. The program also works to raise awareness of HIV among MSM and to advocate increased funding for MSM-targeted services. Community Awards In 2010, amfAR awarded more than $660,000 to 41 groups in Africa, Asia and the Pacific, the Caribbean, Eastern Europe and Central Asia, and Latin America for a wide range of projects addressing HIV prevention, outreach, education, advocacy, testing, research, and capacity building. Africa amfAR awarded funding to nine groups in Africa: Alternatives-Cameroun (Cameroon); Association de lutte contre le sida (Morocco); Espace Confiance (Cte d'Ivoire); Gay and Lesbian Coalition of Kenya in partnership with Ishtar MSM (Kenya); PEMA Kenya (Kenya); South African Network of Religious Leaders Living with or Personally Affected by HIV & AIDS (South Africa); Stop AIDS in Liberia (Liberia); Friends of RAINKA (Zambia); and one organization that requested anonymity (Uganda). Association de lutte contre le sida (Morocco) Association de lutte contre le sida is using its community award in Marrakesh to establish an MSM-friendly drop-in health center, a safe space where MSM can receive social support, medical care, and HIV and syphilis testing and counseling. The group is also creating pamphlets and other materials about HIV and sexually transmitted infections (STIs) for MSM, distributing condoms and lubricant, and sponsoring information sessions in the community. Asia-Pacific Eight organizations in Asia and the Pacific received community awards: Action for AIDS (Singapore); Bandhu Social Welfare Society (Bangladesh); Chengdu Tongle Counseling and Service Center (China); Red Ribbon Initiative (Pakistan); Mplus+ (Thailand); STD/HIV/AIDS Prevention Center (Vietnam); Yayasan Gaya Celebes (Indonesia); and one organization that requested anonymity (India). Chengdu Tongle Counseling and Service Center (China) This group is providing capacity-building support to 18 key MSM/HIV grassroots organizations across China by hiring legal professionals to advise groups about their rights and assist them in fighting human rights violations. In addition to developing a legal manual, the group is cultivating a national network of groups addressing MSM and HIV in order to facilitate technical assistance projects in the future. Caribbean Seven grassroots organizations in the Caribbean received amfAR funding: Centro de Orientacin e Investigacin Integral (Dominican Republic); Fondation Esther Boucicault Stanislas (Haiti); Jamaica Forum for Lesbians, All-Sexuals, and Gays (Jamaica); MSM No Political Agenda (Trinidad and Tobago); SEROvie (Haiti); Society Against Sexual Orientation Discrimination-Guyana (Guyana); and United Belize Advocacy Movement (Belize). SEROvie (Haiti) SEROvie is using its MSM Initiative community award to continue the work it began using a previous award from amfAR to provide outreach and social services for MSM living with and affected by HIV. In addition to building communication skills to promote healthy behaviors, the project provides psychosocial support and referrals to services. SEROvie has also provided basic support for its clients affected by the January 2010 earthquake. Eastern Europe and Central Asia Seven groups in Eastern Europe and Central Asia received community awards from amfAR's MSM Initiative, which was one of the first programs to support HIV services for MSM in the region. Awardees include CSO Equal Opportunities (Tajikistan); New Life Organization (Russia); Nikolaev Regional Public Youth Movement-Penitentiary Initiative (Ukraine); Public Fund Gender Vector (Kazakhstan); Safe Pulse of Youth (Serbia); The Siberian Alternative Center (Russia); and We for Civil Equality (Armenia). Nikolaev Regional Youth Movement - Penitentiary Initiative (Ukraine) The Penitentiary Initiative, a second-year MSM grantee, is using its community award to scale up a program providing HIV outreach to MSM in prison settings, where they are often considered outcasts. Through the program, the group conducts training to reduce stigma and discrimination by prison staff and other prisoners, and provides psychosocial support and HIV prevention for MSM prisoners. Latin America amfAR made community awards to 10 MSM groups in Latin America: Akuaipa Waimakat - Asociacin Para La Divulgacin, Promocin y Defensa de los Derechos Humanos e Indgenas (Colombia); Asociacin ALFIL (Equador); Articulao e Movimento para Travestis e Transexuals de Pernambuco (Brazil); Asociacin Civil De Desarrollo Social Y Promocion Cultural Adesproc Libertad GLBT (Bolivia); Asociacin Un Nuevo Camino ASUNCAMI (Bolivia); Asociacin Solidaria Para Impulsar el Desarrollo Humano (El Salvador); Colectivo SerGay de Aguascalientes A.C. (Mexico); Grupo Gnesis Panam Positivo (Panama); Vallarta Enfrenta el Sida A.C. (Mexico); and one organization that requested anonymity (Brazil). Colectivo SerGay de Aguascalientes A.C. (Mexico) This organization works to reduce the spread of HIV among MSM by engaging peer educators (young men and transgender people) to conduct outreach in parks and bars; distribute condoms, lubricant, and safe sex information; offer peer counseling; and promote LGBT-friendly HIV testing and support services. The group also employs counselors at an LGBT community center to offer support to clients. Publications As part of its efforts to raise awareness among governments, donors, and international nongovernmental organizations of the spread of HIV among MSM and to advocate effective strategies for addressing it, amfAR publishes reports on HIV and MSM. Just prior to the XVIII International AIDS Conference in July 2010, amfAR published a collection of case studies from 10 MSM grantees, Lessons from the Front Lines: Effective Community-Led Responses to HIV and AIDS Among MSM and Transgender Populations. PUBLIC POLICY Informed by thorough research and analysis, amfAR is a highly respected advocate of rational and compassionate AIDS-related public policy. The Foundation is engaged in efforts to secure necessary increases in funding for HIV/AIDS research; implement the new National HIV/AIDS Strategy; expand access to care and treatment; and protect the civil rights of all people affected by HIV/AIDS. Harm Reduction As one of the earliest supporters of comprehensive harm reduction programs for injection drug users (IDUs), including syringe exchange, amfAR has played a leading role in advocating the implementation of these lifesaving programs. In December 2009, the Foundation celebrated a major victory on this front when Congress lifted the ban on federal funding for syringe exchange programs (SEPs). amfAR also funds the only annual national survey of U.S. SEPs, which is traditionally published in the Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report (MMWR). Under contract with the New York State Department of Health's AIDS Institute, amfAR continued to administer the distribution of harm reduction supplies to the 19 authorized SEPs statewide, which have served more than 143,000 registered participants. Shaping the Domestic Response to HIV/AIDS amfAR has long advocated the implementation of a comprehensive national HIV/AIDS strategy to address the ongoing epidemic in the U.S., where more than one million people are living with the virus. In late 2009, amfAR co-sponsored two consultations aimed at developing recommendations for the strategy: one on research and the other on prevention. The Foundation was also a co-author of a paper titled "Moving Beyond the Status Quo," which it provided to the White House Office of National AIDS Policy (ONAP). These efforts culminated in the launch of a National HIV/AIDS Strategy in July 2010, which reflected many of the recommendations set forth by the Foundation and its fellow AIDS advocates. Also in July, Vice President and Director of Public Policy Chris Collins participated in a panel discussion on the strategy at the XVIII International AIDS Conference. Program Service Accomplishments Part III, Line 4a-4d Among those living with HIV in the U.S. are a growing number of young people, many of whom have no idea they are infected. In September 2010, public health experts, researchers, clinicians, and activists gathered for an amfAR-sponsored Congressional briefing on HIV and youth, at which they discussed the complex biological and psychosocial factors driving the spread of HIV among young people, and the multifaceted approaches required to prevent and treat the virus within this diverse population. At the briefing, the Foundation released an issue brief, Youth and HIV/AIDS in the United States: Challenges and Opportunities for Prevention. Global Health In 2010, public policy staff worked with fellow AIDS advocates to argue for increased funding for global HIV/AIDS initiatives, including the President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis and Malaria. In addition to meeting with key administration officials and members of Congress, amfAR released a series of publications making the case for boosting global AIDS funding. In December 2009, the Foundation partnered with the IDSA Center for Global Health Policy on an issue brief, Smart Investments in AIDS and Global Health: Building on What Works. amfAR also prepared several issue briefs on global health in conjunction with the XVIII International AIDS Conference: The Shifting Global Health Landscape: Implications for HIV/AIDS and Vulnerable Populations, HIV/AIDS Investments: Building Blocks for Global Health?, and MSM and the Global HIV/AIDS Epidemic: Assessing PEPFAR and Looking Forward. In March 2010, the public policy office helped organize a Capitol Hill hearing on the importance of increased HIV/AIDS global health funding for the House Foreign Affairs Subcommittee on Africa and Global Health. MSM amfAR's policy office works closely with the MSM Initiative to advocate expanded access to HIV prevention and treatment services for MSM worldwide, and to fight the stigma and discrimination that make MSM more vulnerable to HIV infection and inhibit equal access to care. In addition to publishing its issue brief on MSM and PEPFAR (as described above), the Foundation joined other advocates in opposing a proposed anti-homosexuality bill in Uganda and in calling for a greater focus on MSM in domestic HIV/AIDS prevention programs. AIDS Research Funding Advocating increased funding for lifesaving HIV/AIDS research is another of amfAR's policy priorities. In March 2010, amfAR and the Treatment Action Group released an issue brief, A Sound Investment: The Multiplier Effect of AIDS Research, outlining the ways in which HIV/AIDS research has benefitted other areas of medical research and explaining the importance of sustained funding for the National Institutes of Health. Pre-Exposure Prophylaxis Pre-exposure prophylaxis (PrEP)-which involves giving antiretroviral therapy to HIV-negative people at high risk of becoming infected-holds great promise as a potential prevention intervention. In December 2009, amfAR co-sponsored a think tank on the Intermittent PrEP (iPrEP) research agenda, at which research and policy leaders reviewed current research in this area and suggested priorities for moving forward. HIV and Immigration amfAR's longtime efforts to repeal a ban on travel and immigration to the U.S. by HIV-positive foreigners were rewarded in October 2009, when President Obama announced the end of the ban, which took effect in January 2010. Policies Form 990, Part VI, Section B Line 11 - The Form 990 was prepared by a nationally renowned accounting firm in conjunction with the organization's financial department. A copy of the draft Form 990 was circulated to the full Board of Trustees for discussion and comment. Each Board Member was provided ample opportunity to comment on the information contained in the 990 prior to its filing with the Internal Revenue Service. Line 12 - Each officer, director, trustee and key employee of amFar ("foundation") is required to annually disclose any conflicts of interest that arise by virtue of employment, board service, or position with the foundation. The foundation monitors compliance with its conflict of interest policy through an annual questionnaire/disclosure statement that is distributed to these individuals. Potential conflicts are investigated immediately. Line 15 - amfar ("foundation") undertakes a thorough process to ensure that the executive compensation it pays to its top management official and all of its officers and key employees of organization is reasonable given the market in which the foundation operates. An independent consultant prepares salary ranges and recommendations. Staff compensation is determined by established ranges and established annual salary increase guidelines as determined by CEO and CFO. CEO compensation is submitted for endorsement to the Board's compensation committee. Disclosure Form 990, Part VI, Section C LIne 19 - amfar makes its Form 990 available to the public by retaining a copy at its place of business and on its website, www.amfar.org. The Form 990 is likewise published on the internet at www.guidestar.org. The Foundation's financial statements are made available in its annual report and on its website. The Foundation's governing documents and conflict of interest policy are not ordinarily made available to the public, but, if requested, will be provided at management's discretion. Functional Expenses Part IX, Lines 1 & 3 The Foundation for AIDS Research reports its grants net of grant returns or recoveries. Periodically, grants remitted to charitable organizations are returned to AMFAR for a variety of reason. On Schedules F & I, grants are reported irrespective of whether they were ultimately returned to AMFAR since categorizing the "returned" amounts would be time consuming. Therefore, amounts reported on Part IX, Line 1 will not tie to total grants on Schedule I; amounts reported on Part IX, Line 3 will not tie to total grants on Schedule F. Fundraising Narrative Schedule G, Part I The Foundation for AIDS Research actually paid out $483,987 in fundraising expenses for the year ending September 30, 2010. This amount is reported on Part IX, Line 11(e). For purposes of Schedule G, the Foundation is reporting all amounts paid to the consultants listed on Part I, regardless of whether such amounts were pure fundraising expenses or event production costs. On Schedule G, the total amount paid to the organizations listed is $703,688. Of that $703,688, only $483,987 was paid for fundraising services, the remaining $219,701 was paid for event production services.